• 1
    Folkman J & Shing Y. Angiogenesis. J Biol Chem 1992; 267: 109314
  • 2
    Hanahan D & Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 35364
  • 3
    Brawer MK, Deering RE, Brown M, Preston SD, Bigler SA. Predictors of pathologic stage in prostatic carcinoma: The role of neovascularity. Cancer 1994; 73: 67887
  • 4
    Bigler SA, Deering RE, Brawer MK. Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol 1993; 24: 2206
  • 5
    Siegal JA, Yu E, Brawer MK. Topography of neovascularity in human prostate carcinoma. Cancer 1995; 75: 254551
  • 6
    Walz DA. Thrombospondin as a mediator of cancer cell adhesion in metastasis. Cancer Metastasis Rev 1992; 11: 31324
  • 7
    Lahav J. The functions of thrombospondin and its involvement in physiology and pathophysiology. Biochim Biophys Acta 1993; 1182: 114
  • 8
    Zabrenetzky V, Harris CC, Steeg PS, Roberts DD. Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int J Cancer 1994; 59: 1915
  • 9
    Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, Frazier WA, Roberts DD, Steeg PS. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 1994; 54: 650411
  • 10
    Volpert OV, Lawler J, Bouck NP. A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. Proc Natl Acad Sci USA 1998; 95: 63438
  • 11
    Campbell SC, Volpert OV, Ivanovich M, Bouck NP. Molecular mediators of angiogenesis in bladder cancer. Cancer Res 1998; 58: 1298304
  • 12
    Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 15824
  • 13
    Grossfeld GD, Ginsberg DA, Stein JP et al. Thrombospondin-1 expression in bladder cancer. association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst 1997; 89: 21927
  • 14
    Kieser A, Weich HA, Brandner G, Marme D, Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994; 9: 9639
  • 15
    Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 1995; 55: 61615
  • 16
    Grossfeld GD, Shi SR, Ginsberg DA et al. Immunohistochemical detection of thrombospondin-1 in formalin-fixed, paraffin-embedded tissue. J Histochem Cytochem 1996; 44: 7616
  • 17
    Roberts DD. Regulation of tumor growth and metastasis by thrombospondin-1. FASEB J 1996; 10: 118391
  • 18
    Bleuel K, Popp S, Fusenig NE, Stanbridge EJ, Boukamp P. Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization. Proc Natl Acad Sci USA 1999; 96: 206570
  • 19
    Wight TN, Raugi GJ, Mumby SM, Bornstein P. Light microscopic immunolocation of thrombospondin in human tissues. J Histochem Cytochem 1985; 33: 295302
  • 20
    Ferrer FA, Miller LJ, Andrawis RI et al. Vascular endothelial growth factor (VEGF) expression in human prostate cancer. In situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 1997; 157: 232933
  • 21
    Brown LF, Yeo KT, Berse B, Morgentaler A, Dvorak HF, Rosen S. Vascular permeability factor (vascular endothelial growth factor) is strongly expressed in the normal male genital tract and is present in substantial quantities in semen. J Urol 1995; 154: 5769
  • 22
    Jackson MW, Bentel JM, Tilley WD. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 1997; 157: 23238
  • 23
    Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, Isola J. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 1992; 84: 8837
  • 24
    Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 1993; 53: 336973


  1. Authors

C. Kwak MD, Research Fellow.

R.J. Jin MD, PhD.

C. Lee MD, Research Fellow.

M.S. Park MD, Assistant Professor.

S.E. Lee MD, Professor.


microvessel density


vascular endothelial growth factor